To The Moon

As of the close on Friday,$S&P/ASX 200(XJO.AU)$ closed at 6,954.20 points, down 1.34% in the past 5 days. During the last 5 trading days, $RAMELIUS RESOURCES LTD(RMS.AU)$ was up 10.45%; $FLETCHER BUILDING LIMITED(FBU.AU)$ added 3.70%; $Fisher & Paykel Healthcare Corp(FPH.AU)$ was up 3.55%; $Neuren Pharma(NEU.AU)$ rose 3.44%; and $Gold Road Resources Ltd(GOR.AU)$ increased 3.40%. 1. $RAMELIUS RESOURCES LTD(RMS.AU)$ +10.45%: stock has been rising since it completes Musgrave Minerals acquisition Ramelius Resources is consolidating its acquisition of Musgrave Minerals Ltd through compulsory acquisition after a successful off-market takeover offer. Announced on July 11, 2023, and closed on September 15, 2023, Ramelius Resources made an off-market takeover offer for Musgrave Minerals. Since the close of the deal, RMS stock has been climbing. The compulsory acquisition will be conducted on the same terms as the initial offer. Musgrave shareholders who have not accepted the offer will receive 1 Ramelius share for every 4.21 Musgrave shares, along with $0.04 cash per Musgrave share. Ramelius now holds a 91.37% relevant interest in Musgrave shares. 2. $FLETCHER BUILDING LIMITED(FBU.AU)$: Moody's baa2 credit rating boosts investor confidence FBU received an investment grade credit rating of Baa2 with a stable outlook from Moody's Investors Service. Another possible reason why the AU stock FBU rose this week is because of the general recovery of the construction sector in Australia and New Zealand. The company operates diversified businesses across core markets of New Zealand and Australia, from resource extraction, product manufacturing and distribution through to property development and infrastructure construction. 3. $Fisher & Paykel Healthcare Corp(FPH.AU)$ demonstrates strong earnings growth: Market confidence reflected in rising share prices and high P/E FPH achieved compound earnings per share (EPS) growth of 5.2% per year over the past five years. Despite this, the share price increased at an average annual rate of 9% over the same period, indicating that the market has a higher opinion of the business compared to five years ago. The favorable sentiment is reflected in the company's relatively high price-to-earnings (P/E) ratio of 51.69, suggesting that investors are willing to pay a premium for its earnings. 3. $Neuren Pharma(NEU.AU)$ : Pioneering breakthroughs in brain disorders with strong ROE and impressive 5-year growth Neuren Pharmaceuticals Limited (NEU) is a biopharmaceutical company developing therapies for brain injury, neurodevelopmental and neurodegenerative disorders. Neuren Pharmaceuticals has a high ROE, which is a positive sign. ROE indicates how effectively the company is using shareholders' equity to generate profits. The company has shown considerable five-year net income growth of 34%, outperforming the industry average of 31%. This growth is a strong indicator of the company's financial health and efficiency. 5. $Gold Road Resources Ltd(GOR.AU)$ Increases shareholding of $De Grey Mining(DEG.AU)$ to 19.9% via strategic participation in $300 million placement Gold Road has increased its shareholding in De Grey Mining to 19.9% by subscribing to the two-tranche institutional placement conducted by De Grey Mining. De Grey Mining initiated a fully underwritten two-tranche placement to raise $300 million. The placement was launched on September 28. Gold Road's decision to participate in the placement and increase its shareholding in De Grey Mining indicates confidence in the company's future prospects, specifically in the development of the Hemi gold project. This move aligns with De Grey Mining's strategy to secure funding and support for its mining activities and project development plans.